Latest News

Ocular Therapeutix™ Reports First Quarter 2019 Financial Results and Business Update






BEDFORD, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank"gt;$OCULlt;/agt; lt;a href="https://twitter.com/hashtag/OCUTX?src=hash" target="_blank"gt;#OCUTXlt;/agt;–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the first quarter ended March 31, 2019 and provided a business update. “This is an exciting time at Ocular Therapeutix and it has been a very productive first quarter,” said Antony Mattessich, President and Chief Executive Officer.

Source link




Related posts

STAT Plus: Mallinckrodt to pay $15 million to settle marketing probe, but will fight a charity kickback case

Newsemia

New model captures flexibility of working memory

Newsemia

Medical News Today: Eat fish for a longer life, study suggests

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy